key: cord-0915732-iwjrxlxq
authors: Bhat, Amar; Browning-McNee, Lea Ann; Ghauri, Kanwal; Winckler, Susan
title: COVID-19 Vaccine Confidence Project
date: 2021-06-11
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2021.06.006
sha: 4fdb10cb5e4d48e9eaa347adf7ff56702ab0fae5
doc_id: 915732
cord_uid: iwjrxlxq

nan

1 BACKGROUND 2 Throughout much of 2020 and the beginning of 2021, while COVID-19 continued to grow and 3 spread, government and public health officials worldwide focused on the development and 4 deployment of one or more COVID-19 vaccines as a means of ending the global pandemic. 5

While much of the U.S. Food and Drug Administration's (FDA) attention was correctly placed on 6 ensuring that the vaccines were safe and effective, concern was also growing within the Agency 7 that Americans, particularly those most vulnerable to COVID-19, would choose not to receive 8 the vaccine once available 1 . Public health experts hypothesized that U.S. Government agencies 9 had a major role in understanding, and addressing the concerns of the vaccine hesitant. 2 FDA, 10 in recognizing that they would need to communicate with the public about any authorized or 11 approved vaccine, wanted to better understand those concerns and be prepared with 12 message(s) that would respond to those concerns. American newspapers as well as papers in selected markets, news magazines, national 50 broadcast outlets, wire services, and one online resource (WebMD) on the topic of a COVID-19 51 vaccine. A number of these media organizations also conducted independent polls during the 52 summer and fall of 2020 to ascertain Americans' sentiment around a potential COVID-19 53 vaccine; those poll results were included in the analysis. 54

To assess Americans' attitude in social media, the media analysis concentrated on four major 56 sources: Facebook, Pinterest, Instagram, and Twitter. A large variety of public groups, 57 platforms, and profiles were surveyed to assess conversations, with less attention to anti-58 vaccine content. Key words used to find appropriate conversations included #covid, #covid19, 59 #vaccine, #fda, and #covidvaccine, as well as combinations of hashtags and key words. 60

Considerations included review of these platform policies to monitor or restrict misleading or 61 negative content regarding COVID-19 vaccines. with their views or type responses in the chat if they preferred (virtual sessions only). To the 83 extent possible, moderators took steps to reduce bias by remaining neutral and objective 84 throughout the discussion, i.e., no opinions were offered, nor any attempt to correct 85 misinformation. We conducted ten sessions using videoconferencing technology and four in-86 person (in accordance with then-current physical distancing and mask-wearing 87 recommendations). Each session took approximately 60 minutes. See Table 1 Respondents were provided a small remuneration for taking the omnibus survey. 100

The participants in the online survey were asked two questions: 101 102 1. How convincing do you find the following messages (see Table 2 regarding what information to believe. All participants noted how the lack of credible and 142 accurate information was a major obstacle in choosing to receive a COVID-19 vaccine, when 143 available. Participants identified politics, social media, misinformation, and the newness of 144 COVID-19 for the lack of credible information. Available information about the vaccine was 145 viewed as confusing, overwhelming, and contradictory. Participants varied in what information 146 they wanted to hear, including about adverse effects, adequate explanation of the 147 development process, and addressing various myths and theories. 148 149 A related concern was the fear that the vaccine will not work for themselves and their family 150

because the vaccine was not tested adequately in their particular sub-population. Most 151 participants were reluctant to be first in line to receive a vaccine. Many expressed a "wait-and-152 see" or "you-first" approach, preferring to monitor the results of the vaccines on others before 153 considering the vaccine for themselves (with timelines from 2 months to "30 years"). 154 155 Another strong concern was the worry that economics and politics were being prioritized over 156 science and public health. People worried that politicians were interfering in vaccine 157 development for political gain. Many felt that the speed of development meant that potential 158 vaccines would not be adequately studied for safety, effectiveness, and side effects. Some felt 159 that the speed of the process reflected a politicization of the review process or that companies 160 were speeding development to enhance their profits. For example, participants intimated 161 manufacturers might skip steps in the development process or oversight agencies might adjust 162 the review process to meet deadlines imposed by political leaders. Participants assumed that 163 vaccines influenced by desire for political gain or increased profit would be less effective and 164 safe than those made with a focus on science and public health. 165 166 A final primary theme was the lack of trust in government, especially among people of color. 167

Some people of color worried the health system will treat them like "guinea pigs". These 317 Sample messages that "show" rather than merely "tell" include: 318 "Only safe and effective COVID-19 vaccines that have been rigorously tested on tens of 319 thousands of volunteers will be approved." 320 "COVID-19 vaccines are following the same rigorous, three-phased testing process as 321 every other vaccine." 322 "The FDA will publicly share information about COVID-19 vaccines so you can see the 323 evidence for yourself." 324 325 Tailor messages to the audience. The foundation of health communication is that "one 326 message does not fit all." While our listening sessions made clear that consistent information 327 on COVID-19 vaccines is essential, those messages need to be strategically personalized. One 328 approach is to move the message from the abstract ("vaccines can help stop the spread of 329 COVID-19") to the familiar ("Getting a vaccine can help protect your family"). The latter 330 message is personalized ("your family"), makes an emotional link ("protect"), and speaks to 331 action ("Getting a vaccine"). Using emotional connections can be tricky; we found that some 332 audiences responded negatively to use of shame or morality messaging. For some traditionally-333 underrepresented audiences, invoking the concept of duty to country or community did not 334 increase likelihood of taking the vaccine and in some cases elicited a negative emotion. 335 336 Explain the process. Four of our top five performing messages address the vaccine 337 development process -specifically concerns about speed and safety. Key words/phrases, such 338 as "rigorous" and "see the evidence for yourself," were highlighted in expert interviews while 339 all testing showed that messages of reassurance (such as promising transparency and 340 explaining that steps were not skipped) were critical. Messages about process need to be 341 tailored to the audience. Keep it digestible and high-level for most groups with direction to 342 additional resources for healthcare providers who are communicating with patients. while a few participants would likely never take the vaccine, many others were hesitant, clearly 376 wanting more information before making a decision. Many Americans want a COVID-19 377 vaccine, even if they want more information about its safety before agreeing to receive the 378 vaccine. About 64 percent of respondents in our poll said they are "likely" to get a COVID-19 379 vaccine once approved. 380 381 Be ready to respond to vocal critics. There will always be those with ingrained concerns about 382 any vaccine who are likely to be outspoken about their views. Effective communication takes 383 into consideration that those who are vaccine hesitant will hear this information and possibly 384 become even more concerned, making it even more important that messages correct 385 misinformation (including intentional falsehoods and conspiracy theories) to prevent confusion 386 or unfounded concern. 387 388

After months of living with anxiety and uncertainty, as well as incalculable human and 390 economic loss, we now have a light at the end of the tunnel with the authorizations and public 391 availability of at least three COVID-19 vaccines (as of April 2021), providing the potential for 392 herd immunity in the U.S. population. To achieve that goal, it is important that trusted 393 messengers be equipped to address the concerns, and answer the questions, of those who 394 express hesitancy to get the vaccine. This will help to ensure that Americans understand that 395 vaccination will be an effective way to put an end to the COVID-19 pandemic. The 396 recommendations that we developed through the findings from the listening session and 397 message testing can be leveraged by public health experts to encourage Americans to receive 398 the vaccine. 399 400 However, efforts to address COVID-19 vaccine hesitancy should include ongoing attempts to 401 engage the public, gather their questions, and provide responses effectively. As we learned 402 from the listening sessions, Americans want reassurance that a vaccine is safe, but they also 403 need to be engaged in a process that fosters trust and understanding. FDA will continue to 404 disseminate these recommendations broadly to inform COVID-19 vaccine outreach efforts at 405 the local, state, and national levels. Sharing clear, evidence-based information will not only help 406 start the conversation about vaccines, but will collectively move us to the point where we can 407 end this pandemic. 408 409 Table 1 :

African American/black men and women in a Southern urban area Black and Latinx community leaders in a Midwest urban area English as second language/Latinx families and individuals in a Mid-Atlantic suburban area Indigenous/Native people from 11 tribes and villages Indigenous/Native people providing social services to 400 tribes and villages Clinical staff such as medical technicians, nurses, nursing assistants, orderlies, and physicians Non-clinical staff in food service, IT, and custodial roles Community and public health leaders of color in underserved communities Hourly sales associates at retail stores in rural and urban settings Mid-level managers of retail stores J o u r n a l P r e -p r o o f Original Messages as Tested Only safe and effective COVID-19 vaccines that make it through the rigorous, threephased testing process will be available. COVID-19 vaccines are following the same rigorous, three-phased testing process as every other vaccine. COVID-19 vaccine development is moving faster than normal because our top medical experts have made it their highest priority, not because steps in the testing process are being skipped. The FDA will share information about approved COVID-19 vaccines so you can see the scientific evidence for yourself. COVID-19 vaccine developers are trying to make sure their clinical trials reflect the nation's diversity, because these vaccines must be proven safe and effective for everyone. Medical experts and career public health officials, not politicians or their appointees, will decide when a COVID-19 vaccine is safe, effective, and ready for FDA approval. Your health care professional is a trustworthy source of information about a COVID-19 vaccine. If you don't get a COVID-19 vaccine, you risk spreading the deadly virus to your loved ones and prolonging the pandemic. The sooner you get a COVID-19 vaccine, the sooner your work, school, and social life can return to normal. By getting a COVID-19 vaccine, you are protecting your child, parents, grandparents, or other loved ones.

J o u r n a l P r e -p r o o f "I need to know that all the minorities who took it are okay. I need to know it works for everybody. I am not trying to be harmed." "Indian people are different biologically but then who constitutes as Indian -half Indian?" "Unless there is a specific study done with us and our specific make-up, we are going to be incidentally immune with a vaccine that is studied with a proportionally lower number of participants in the study group." Distrust of Government "Who can we trust? That's the million-dollar question." "I also hear so many people arguing about the pros and the cons. Mostly cons because of distrust of the government from past experience." "When COVID first came out, I trusted the CDC website and was sharing from there. Now I trust the FDA and CDC much less than I did when this first came out." "I don't think the FDA can be trusted to keep people safe." "When I hear the FDA say they have a particular process, but then I hear the White House say they can cut that in half or negate it -it brings more distrust." Concern about the Speed of the Process "The speed is appreciated, but there are questions." "They want to get one out as soon as possible. Which I don't think is very safe." "We all know how long vaccines take, so to hear that it will be ready in a few months is concerning." "I would not be first in line and I would want to see some data." "Vaccines takes years to develop and test. For them to try to do it in a year is pretty absurd."

J o u r n a l P r e -p r o o f Table 4 :

The FDA is publicly sharing information about COVID-19 vaccines so you can see the evidence for yourself. Only safe and effective COVID-19 vaccines that have been rigorously tested on tens of thousands of volunteers will be approved. Scientists and career public health officials, not politicians or their appointees, will decide when a COVID-19 vaccine is safe, effective, and ready for public use. By getting a COVID-19 vaccine, you are protecting yourself, your children, parents, grandparents, and other loved ones. COVID-19 vaccine development is moving faster than normal because the medical and scientific community have made it their highest priority, not because any steps have been skipped.

J o u r n a l P r e -p r o o f Various medical professionals and experts were the three most-trusted types of messengers to respond to concerns. Federal elected officials and high-profile celebrities were near the bottom. 

Facilitate COVID-19 Vaccine Uptake in the United States. Health Security

Landscape Analysis: COVID-19 Vaccine Perceptions

Interim Report Vaccine Conifdence Project: Listening Sessions2020. 439 (unpublished) 440 5. Center of Disease Control and Prevention

COVID-19 Vaccine Confidence Project

How Elvis Got Americans to Accept the Polio Vaccine. Behavior 446 & Society

Many people helped to complete this project. Ms. Heather Cobb prepared the media analysis, 411Dr. Chrisanne Wilks helped to organize, and prepared the analysis of, the listening sessions, and 412Hamilton Place Strategies drafted the initial messages and conducted the message testing. We 413 acknowledge the many people and organizations who assisted with our listening sessions. vaccine. 2020; https://apnews.com/article/racing-for-a-remedy-virus-outbreak-donald-432